259 related articles for article (PubMed ID: 30001990)
1. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC; Gray MD; Mannaris C; Folkes LK; Stratford M; Campo L; Chung DYF; Scott S; Anderson M; Goldin R; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
Lancet Oncol; 2018 Aug; 19(8):1027-1039. PubMed ID: 30001990
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.
Lyon PC; Griffiths LF; Lee J; Chung D; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
J Ther Ultrasound; 2017; 5():28. PubMed ID: 29118984
[TBL] [Abstract][Full Text] [Related]
3. Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.
Gray MD; Lyon PC; Mannaris C; Folkes LK; Stratford M; Campo L; Chung DYF; Scott S; Anderson M; Goldin R; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
Radiology; 2019 Apr; 291(1):232-238. PubMed ID: 30644817
[TBL] [Abstract][Full Text] [Related]
4. Large-Volume Hyperthermia for Safe and Cost-Effective Targeted Drug Delivery Using a Clinical Ultrasound-Guided Focused Ultrasound Device.
Lyon PC; Mannaris C; Gray M; Carlisle R; Gleeson FV; Cranston D; Wu F; Coussios CC
Ultrasound Med Biol; 2021 Apr; 47(4):982-997. PubMed ID: 33451816
[TBL] [Abstract][Full Text] [Related]
5. Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia.
Staruch RM; Ganguly M; Tannock IF; Hynynen K; Chopra R
Int J Hyperthermia; 2012; 28(8):776-87. PubMed ID: 23153219
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermia-mediated doxorubicin release from thermosensitive liposomes using MR-HIFU: therapeutic effect in rabbit Vx2 tumours.
Staruch RM; Hynynen K; Chopra R
Int J Hyperthermia; 2015 Mar; 31(2):118-33. PubMed ID: 25582131
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
Spiers L; Gray M; Lyon P; Sivakumar S; Bekkali N; Scott S; Collins L; Carlisle R; Wu F; Middleton M; Coussios C
BMC Cancer; 2023 Sep; 23(1):896. PubMed ID: 37741968
[TBL] [Abstract][Full Text] [Related]
8. Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer.
Mikhail AS; Negussie AH; Pritchard WF; Haemmerich D; Woods D; Bakhutashvili I; Esparza-Trujillo J; Brancato SJ; Karanian J; Agarwal PK; Wood BJ
Int J Hyperthermia; 2017 Nov; 33(7):733-740. PubMed ID: 28540814
[TBL] [Abstract][Full Text] [Related]
9. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.
Tak WY; Lin SM; Wang Y; Zheng J; Vecchione A; Park SY; Chen MH; Wong S; Xu R; Peng CY; Chiou YY; Huang GT; Cai J; Abdullah BJJ; Lee JS; Lee JY; Choi JY; Gopez-Cervantes J; Sherman M; Finn RS; Omata M; O'Neal M; Makris L; Borys N; Poon R; Lencioni R
Clin Cancer Res; 2018 Jan; 24(1):73-83. PubMed ID: 29018051
[No Abstract] [Full Text] [Related]
10. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
[TBL] [Abstract][Full Text] [Related]
11. Focused Ultrasound Hyperthermia Mediated Drug Delivery Using Thermosensitive Liposomes and Visualized With
Santos MA; Goertz DE; Hynynen K
Theranostics; 2017; 7(10):2718-2731. PubMed ID: 28819458
[TBL] [Abstract][Full Text] [Related]
12. Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in
de Maar JS; Suelmann BBM; Braat MNGJA; van Diest PJ; Vaessen HHB; Witkamp AJ; Linn SC; Moonen CTW; van der Wall E; Deckers R
BMJ Open; 2020 Nov; 10(11):e040162. PubMed ID: 33243800
[TBL] [Abstract][Full Text] [Related]
13. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.
Zagar TM; Vujaskovic Z; Formenti S; Rugo H; Muggia F; O'Connor B; Myerson R; Stauffer P; Hsu IC; Diederich C; Straube W; Boss MK; Boico A; Craciunescu O; Maccarini P; Needham D; Borys N; Blackwell KL; Dewhirst MW
Int J Hyperthermia; 2014 Aug; 30(5):285-94. PubMed ID: 25144817
[TBL] [Abstract][Full Text] [Related]
14. Surrogate MRI markers for hyperthermia-induced release of doxorubicin from thermosensitive liposomes in tumors.
Peller M; Willerding L; Limmer S; Hossann M; Dietrich O; Ingrisch M; Sroka R; Lindner LH
J Control Release; 2016 Sep; 237():138-46. PubMed ID: 27364227
[TBL] [Abstract][Full Text] [Related]
15. Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery.
Borys N; Dewhirst MW
Adv Drug Deliv Rev; 2021 Nov; 178():113985. PubMed ID: 34555486
[TBL] [Abstract][Full Text] [Related]
16. Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy.
Rezaeian M; Sedaghatkish A; Soltani M
Drug Deliv; 2019 Dec; 26(1):898-917. PubMed ID: 31526065
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
Merle P; Blanc JF; Phelip JM; Pelletier G; Bronowicki JP; Touchefeu Y; Pageaux G; Gerolami R; Habersetzer F; Nguyen-Khac E; Casadei-Gardini A; Borbath I; Tran A; Wege H; Saad AS; Colombo M; Abergel A; Richou C; Waked I; Yee NS; Molé A; Attali P; Le Boulicaut J; Vasseur B;
Lancet Gastroenterol Hepatol; 2019 Jun; 4(6):454-465. PubMed ID: 30954567
[TBL] [Abstract][Full Text] [Related]
18. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
19. Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors.
Hong CW; Chow L; Turkbey EB; Lencioni R; Libutti SK; Wood BJ
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):409-16. PubMed ID: 26228246
[TBL] [Abstract][Full Text] [Related]
20. The effect of injected dose on localized tumor accumulation and cardiac uptake of doxorubicin in a Vx2 rabbit tumor model using MR-HIFU mild hyperthermia and thermosensitive liposomes.
Cheng B; Bing C; Staruch RM; Shaikh S; Wodzak Staruch M; Szczepanski D; Williams NS; Laetsch TW; Chopra R
Int J Hyperthermia; 2020; 37(1):1052-1059. PubMed ID: 32892667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
